Jefferies’ Post

LPX50 constituent company, Apax Global Alpha Limited (AGA) has announced the sale of investment in Healthium Medtech Limited. According to the press release, this transaction values AGA's look-through investment in Healthium at approximately €22.7M. This represents an uplift of c.23% to the last Unaffected Valuation1 and an uplift of c.€4.3m (c.€0.01 per share / c.£0.01 per share) in the Adjusted Net Asset Value ("Adjusted NAV") of AGA at 31 March 2024. The transaction is expected to close in Q3 2024, subject to regulatory approvals. 🔷 Link to official press release 👉 https://lnkd.in/dTgqEV3w 🔷 Subscribe to Listed Private Equity Barometer published by LPX AG 👉 https://lnkd.in/ex-E8nej   Disclaimer: This content is provided for informational purposes and none of the content here should be construed as financial advice or an offer or solicitation for securities. The content is not intended to provide a sufficient basis on which to make an investment decision. The past performance is not indicative of future results.   #privateequity #alternativeinvestments #privatemarkets #investments #listedprivateequity #technology #business #investing #medical #health #healthcare

Exciting News Update! US-based KKR has finalized the acquisition of Bengaluru-based Healthium Medtech, a prominent Indian medical devices company, from Apax Partners for Rs 7,000 crore. #KKR #HealthiumMedtech #Acquisition #MedicalDevices #Investment #GlobalPartnerships KKR, a renowned global investment giant, has valued Healthium Medtech at Rs 7,000 crore, marking a significant move in the Indian medical devices industry. Healthium Medtech, a key player in surgical needles and sutures, is set to accelerate its growth under KKR’s ownership. #Healthcare #SurgicalDevices #StrategicInvestment #IndianIndustry The acquisition facilitates KKR’s entry into the thriving Indian healthcare sector and underscores its commitment to fostering innovation and excellence in medical technologies. Healthium Medtech's robust product offerings and expansion plans align seamlessly with KKR’s vision for sustainable growth and development. #Innovation #MedicalInnovations #GlobalExpansion #Sustainability

Join our experts, Praveen Raju and Mathew Chacko, in this interactive discussion on India's USD650+ billion Life Sciences industry (2025 projection). From major investments and acquisitions to regulatory challenges surrounding IP and data, Praveen and Mathew will share their experience and expertise in this space. Mondaq Register here: https://lnkd.in/dquxsHVX #spiceroutelegal #lifesciences #lifesciencesindustry #healthcare #healthcarecompliance #regulations #globaltrends #India #webinars #legalinsights #mondaq

Private Equity within Medtech continues to become more and more prevalent. Investments into established revenue generating family owned businesses, portfolio companies with multiple manufacturing locations they can build around, and new focus on the ambulatory surgical center markets are where the puck is heading with private equity as it relates to #MedTech. If you are an individual in the market looking for new things, it would be worth evaluating companies that are PE backed. - The risk from a regulatory standpoint has typically has been mitigated - PE tends to acquires revenue generating companies - Stronger opportunity for M&A / inorganic growth activities - Building a new and broader network of key players for your career development - Higher likelihood of a liquidity event In this clip, Joe Mullings and I discuss the PE model and why it would be beneficial to evaluate PE backed companies for your next move. #medtech #privateequity #PE #careeradvice The Mullings Group

🩺🌏A stark and fiscal look at the current state of the medtech sector. As global medtech leaders converge to Anaheim, CA for AdvaMed's annual Medtech Conference, EY published their Pulse of the Industry: Medical Technology Report 2023 this Monday with a glaring look into the ongoing market headwinds. While the report outlines several critical challenges, it also offers perspective on how the medtech sector can restore its growth trajectory and kick-start a much-needed global resurgence. Full EY report:https://lnkd.in/enNQQ2m9 #medicaldevice #medtechmoney #medtechmarketinsights #globalmedtech The Mullings Group MedTech Dive

So much richness in this report from EY — especially the sobering analysis of flagging medtech sector growth. As they say, the first step in fixing a problem is admitting you have one. The root of the problem is a slowdown in true innovation. This is driven primarily by declining R&D investment on the one hand, coupled with a retreat from inorganic growth (M&A) by large strategics in the other. It’s widely accepted that a healthy ecosystem is one where there’s a symbiotic relationship between the larger and smaller players. This is the wellspring of innovation. But the pullback by strategics would tend to harm innovation in the sector more broadly. And the timing of this could not be worse. Here’s the reason why according to EY: “Rapidly evolving technologies, increasingly sophisticated consumer demand for more personalized and convenient health care, pressure to change payment models due to aging populations and a rise chronic disease incidence are all long-term trends that have unavoidable and significant implications for the industry and will ultimately lead health leaders to rethink how care should be delivered in the future.” The current blueprint for medtech innovation hasn’t made a compelling case for its ability to solve these challenges. Especially not in a depressed innovation environment. This won’t change until the industry gets back to its roots and continues to collaborate across the ecosystem to drive the kind of breakthrough innovation needed to get back to differentiated, innovation-driven growth. The path forward is: * a reinvigoration of innovation focus * rebuilding partnerships & collaboration across the ecosystem * attracting the blue-flame thinking (talent) needed to solve the problems posed by the new data-driven, connected, integrated, and patient-centered reality facing the medtech industry. EY offers a point of view on how to do this: “Our vision for the future direction of life sciences is the technology-driven reinvention of the sector, which we call the intelligent health ecosystem (IHE). The IHE is a blueprint for a smart, connected, personalized, patient-centered health care model for the future. Within this new model, health care will be: * Built on ecosystem-wide collaboration and frictionless data sharing between parties * Delivered by a seamless integration of virtual and digital care channels * Enabled by the convergence of new technologies and data, and capable of delivering value for all stakeholders” Easy to say, hard to do. But that’s where true differentiation lies. And the time for leaders to step into the void is now. Exciting times for this massive, vital, and dynamic industry. #medtech #innovation